Advertisement

Oncology / Hematology General

Leukemia Relapse Associated with TIGIT- and CD161-expressing CD4 T Cells

Nov 01, 2022

The best course of treatment for certain patients with acute myeloid leukemia (AML) is allogeneic hematopoietic stem cell transplantation (allo-HSCT), which depends on a "graft-versus-leukemia" effect...

In Hematopoietic Stem Cells, Physioxia Induces Tet2 Downregulation

Nov 01, 2022

When exposed to ambient air as compared to physioxia, hematopoietic stem cells (HSCs) exhibit decreased recovery and self-renewal with a concurrent increase in differentiation. Although the mechanism(...

Tranexamic Acid as A Prophylactic Treatment for Hematologic Malignancies

Oct 31, 2022

There was insufficient proof that tranexamic acid (TXA) used as a preventative measure in thrombocytopenia worked. From June 2016 to June 2020, randomized, double-blind clinical research was carried o...

Classifying Hematologic Neoplasms in The Era of Precision Medicine

Oct 31, 2022

Clinical advisory panels made up of pathologists, hematologists, oncologists, and genomic scientists provided the bulk of the input for the recently created International Consensus (IC) categorization...

Durvalumab with Stage III Non–Small-Cell Lung Cancer: Study

Oct 28, 2022

Patients with stage III non-small-cell lung cancer that was unresectable and who were still alive after concomitant chemotherapy (cCRT) and radiation treatment benefited considerably from the use of d...

Metastatic Urothelial Carcinoma and Genomic Characterization Reveal a Novel Biomarker

Oct 28, 2022

Patients with metastatic urothelial carcinoma (mUC) were characterized, potential biomarkers were identified, and a bladder immune performance index  (BIPI) was developed through the use of de-identi...

Donor pDCs Limit GVHD Through VIP Expression

Oct 27, 2022

To prevent graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplant (HSCT) recipients, vasoactive intestinal polypeptide (VIP), an anti-inflammatory neuropeptide with pleiotro...

Allogeneic Transplantation Role in CMML

Oct 27, 2022

For a study, researchers sought to put together a retrospective cohort of chronic myelomonocytic leukemia (CMML) patients 18–70 years diagnosed between 2000 and 2014 from an international CMML datas...

Phase 3 Trial of MCL0208 by The Fondazione Italiana Linfomi

Oct 27, 2022

In mantle cell lymphoma (MCL), minimal residual disease (MRD) analysis is a well-known prediction method. In the first prospective thorough analysis of various techniques, molecular markers, and tissu...

In Thrombocytopenic Purpura, Race, Rituximab, And Relapse

Oct 27, 2022

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) are characterized by recurrent thrombotic microangiopathy events that impair ischemic organ function. Black patients make up a disproportiona...

Glioma Patients' Circulating Extracellular Vesicle RNA Detection of EGFRvIII

Oct 27, 2022

When it comes to glioblastoma, the ability to noninvasively diagnose the disease, assess its prognosis, and foretell its clinical outcomes, the liquid biopsy platform is appealing. Previous research h...

Precise Gene Expression Signatures Have Been Developed to Reflect Phenotypic Changes

Oct 27, 2022

To better understand and diagnose cancer, precise mechanism-based gene expression signatures (GES) have been created in relevant in vitro and in vivo model systems. Some GESs, however, are now being a...

Transcriptomic: TC PD-L1 Expression & Nivolumab Monotherapy

Oct 26, 2022

The relevance of PD-L1 expression on tumor cells (TC) in clear cell renal cell carcinoma (ccRCC) is debatable. However, it is known to be related to responsiveness to anti-PD-1-based therapy in some t...

NUDT15 Expression Levels: Biallelic NUDT15 Variants & 6-MP Intolerance

Oct 21, 2022

Pediatric lymphoma and leukemia are commonly treated with 6-Mercaptopurine (6-MP). Germline variations in the NUDT15 gene have recently been discovered to be one of the main genetic reasons for the ne...

Clinicopathological Characteristics & Plasmablastic Lymphoma

Oct 21, 2022

There was no standard of treatment for the aggressive and uncommon subtype of non-Hodgkin lymphoma known as plasmablastic lymphoma (PBL). For a study, researchers examined every patient in British Col...

Nivolumab Plus Ipilimumab Vs. Chemotherapy: Survival Outcome

Oct 21, 2022

For a study, researchers sought to provide 5-year findings from CheckMate 227 Part 1 in which nivolumab with ipilimumab, regardless of tumor programmed death ligand 1 (PD-L1) status, increased overall...

DNA Replication Regulator ORCs in Lung Adenocarcinomas

Oct 21, 2022

Patients with lung adenocarcinoma (LUAD) is characterized by DNA replication alteration, which is typically seen during LUAD development. Origin recognition complex (ORC) 1, ORC 2, ORC 3, ORC 4, ORC 5...

Eltrombopag & Azacitidine in High-risk Myelodysplastic Syndromes Patients

Oct 20, 2022

Thrombocytopenia is made worse when myelodysplastic syndromes with high risk are treated with azacitidine. Therefore, Eltrombopag and azacitidine were studied using a 3 + 3 cohort design. Eltrombop...

Palladin Promotes CSCs-like Properties in Lung Cancer

Oct 20, 2022

Drug resistance, cancer recurrence, and metastasis are all caused by cancer stem cells (CSCs). For a study, researchers sought to present the results of the initial investigation into Palladin express...

Thrombotic Risk Factors in 1381 ET Patients: Validation

Oct 20, 2022

Patients with essential thrombocythaemia (ET) frequently have thrombosis and hemorrhage. Patients were divided into 4 risk categories according to the 2016 revision of the International Prognostic Sco...